Search Results 1211-1220 of 19037 for Neutrophil

1. Belimumab With Rituximab for Primary Membranous Nephropathy (REBOOT) - Mayo Clinic

   Absolute neutrophil count \< 1.5 x 103/?l 16. Moderately severe anemia (hemoglobin \< 9 g/dL) 17. History of primary immunodeficiency 18. Serum IgA \< 10 mg ...

2. A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501) - Mayo Clinic

   Absolute neutrophil count (ANC) greater than 500/µL. Biopsy confirmation of GVHD is not required. Enrollment should not be delayed for biopsy or pathology ...

3. A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) - Mayo Clinic

   ... neutrophil count ≥1.0 x 10/L * Adequate organ function * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Estimated creatinine clearance ...

4. Low white blood cell count - Mayo Clinic

   This is because labs set their own reference ranges based on the people they serve. Most often, a count lower than 3,500 white blood cells per microliter of ...

5. Lenalidomide And Dexamethasone With Or Without Bortezomib In Treating Patients With Previously Untreated Multiple Myeloma - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1 x 10^3/mcL; must be obtained within 28 days prior to registration; Exception: patients with biopsy-proven heavy-marrow ...

6. Pharmacokinetic and Safety Study of Nab ®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects with Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500 (1.5 × 109/L) cells/mm3;; Platelet count ≥ 100,000 (100 × 109/L) cells/mm3;; Hemoglobin (Hgb) ≥ 9 g/dL. Subject has ...

7. Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcL without the use of hematopoietic growth factors. Platelets ≥ 100,000/mcL. Total bilirubin below normal institutional ...

8. Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA) - Mayo Clinic

   Absolute neutrophil count ≥000/μL;; Platelet count ≥5000/μL;; Total bilirubin (TBL) ≤.0× upper limit of normal (ULN);; AST and ALT ≤×ULN;; Albumin ≥.8 g/dL ...

9. A Study of Healthy Donor Volunteers to Provide Blood components Via Leukapheresis for In vitro Dendritic Cell Investigations - Mayo Clinic

   The purpose of this study is to collect blood cells as a healthy donor for use in research studies, which will focus especially on using the immune system's ...

10. Study of AMG 650 in Adult Participants With Advanced Solid Tumors - Mayo Clinic

    Absolute neutrophil count (ANC) ≥ 1.5 x 10^9 /L without growth factor support within 7 days (G-CSF) or 14 days (pegylated G-CSF) from screening assessment; ...